Clinical trial · Observational
Blood Test for Ovarian Cancer Associated Antibodies (CAAb)
Study to Assess the Effectiveness of the CAAb Test With Ovarian Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Blood is collected from patients and cultured in a CimTube (a test tube with stimulation media) for several days. Following the culture step, the supernatant fluid is tested for the presence of CAAb on experimental test kits. Null Hypothesis: There is no relationship between the presence or absence of ovarian cancer (OC) and the CAAb i.e. d=0. Alternative Hypothesis: The expectation of the CAAb in the cancer population differs from that of the control population, i.e. m1 is not equal to m2. Since the sign of the difference is not important, the test will be two-sided.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Find Cancer Associated Antibodies | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Ovarian cancer patients: * Subjects 18 years or over. * Patients suspected of ovarian cancer (including peritoneal carcinoma). The clinical suspicion will include one of the following: pelvic mass (by pelvic examination or other imaging techniques), or high cancer antigen (CA)-125 levels in post-menopausal women, ascites, or due to incidental finding of distant metastasis. Final analysis will be done in relation to pathology only. * Patients willing to participate as evidenced by signing the written informed consent. Control subjects: * Subjects 18 years or over * Patients willing to participate as evidenced by signing the written informed consent Exclusion Criteria: Ovarian cancer patients: * Subjects less than 18 years of age * Hematological malignancies * Previous ovarian tumor * Patients under active chemotherapy treatment * Patients not willing to sign written informed consent Control subjects: * Subjects less than 18 years * Hematological malignancies * History of any past tumors * Other ovarian pathology * Patients who have been under anesthesia in the last 2 months * Patients treated with immunosuppressant drugs * Patients not willing to sign written informed consent
References
Publications (0)
Data not yet available